Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H

As of June 30, 2026, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H carries a market capitalization of 3.85B, placing it among publicly traded companies globally. Its enterprise value stands at 3.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H has 134.52M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H maintains a current ratio of 18.58, meaning it holds 18.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 28.98, while the 200-day moving average is 25.76.

As of June 30, 2026, Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H holds 629.06M in cash and equivalents against 85.23M in total debt, resulting in a net debt position of -501.02M. Total book value stands at 731.04M, with working capital of 667.64M providing operational flexibility.